NEW YORK (GenomeWeb News) – Danish diagnostics firm Dako today said that it has signed an agreement to provide companion diagnostics for Genentech's trastuzumab (Herceptin) for patients with advanced HER2-positive stomach cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.